HIV
News from the FDA/CDC
HIV testing still suboptimal
“If we just look at the need for HIV testing based on who is at risk, I think that we are always going to fall short.”
Conference Coverage
Long-acting ART effective without viral suppression
“Instead of having the burden of taking a pill every day, patients with HIV can now have these choices of being able to forget about their...
Latest News
Doxy PEP does not lower risk of STIs in cisgender women
Women are known to be at higher risk of infection because the lining of the vagina is thinner than the skin of the penis, allowing for easier...
From the Journals
Scientists create ‘vagina on a chip’: What to know
Researchers see the chip as a way to facilitate vaginal health research and open the door to vital new treatments.
Feature
Highly anticipated HIV vaccine fails in large trial
The vaccine had been in development since 2019 and was given to 3,900 study participants through October 2022.
Latest News
Kaposi’s sarcoma: Antiretroviral-related improvements in survival measured
From 2004 to 2018, patients with HIV had lower 1- and 2-year overall survival rates than those of the uninfected.
News
FDA approves first-in-class drug for HIV
FDA has approved the medication lenacapavir (Sunlenca) for adults living with multidrug resistant HIV-1 infection.
Latest News
Systematic review supports preferred drugs for HIV in youths
Findings support the use of dolutegravir an raltegravir as part of WHO-recommended regimens for treating HIV.
From the Journals
HIV vaccine trial makes pivotal leap toward making ‘super antibodies’
“The trial results show that one can design vaccines that induce antibodies with prespecified genetic features, and this may herald a new era of...
From the Journals
CAB-LA’s full potential for HIV prevention hits snags
Issues include breakthrough infections despite timely injections, complexity of follow-up, logistical considerations, and its cost-effectiveness...
From the Journals
Pregnancy outcomes on long-acting antiretroviral
“It can be dosed monthly or every 2 months ... This could be a consideration for women who might have problems tolerating oral pills during...